NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$29.82
-1.45 (-4.64%)
▼
5d:
-3.12%
30d:
+16.35%
90d:
+71.58%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Smart Money Accumulation
NGNE is down 3.1% this week, but smart money is accumulating calls. Top strike: $35 2026-06-18 with 36 OI. Call ratio: 98% View Scanner →
Strength: 6.3/10
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NGNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NGNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $29.82, which is considered slightly high relative to its 30-day fair value range of $23.70 to $30.85.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $26.22, while resistance sits at $33.99. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $80.00 (+168.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $26.22, while resistance sits at $33.99. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $80.00 (+168.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$23.70 -
$30.85
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
69.6%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 168.3% below Wall St target ($80.00)
Trading Range Analysis
30-Day Trading Range
$23.70 -
$30.85
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$4.81
(16.1%)
Support & Resistance Levels
Support Level
$26.22
Resistance Level
$33.99
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.34
Wall Street Target
$80.00
(+168.3%)
Share & Embed Analysis
Last updated: May 18, 2026 8:19 AM ET
Data refreshes hourly during market hours. Next update: 9:19 AM
Data refreshes hourly during market hours. Next update: 9:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Mikail Cvijic
SELL
4045 shares
2026-03-13
Stuart Cobb
SELL
6797 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$126 | 48 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$106 | 56 HOLD |
